SEP 28, 2023 12:30 PM CEST

Immunotherapy Insights: Biomarker Testing and Multi-Disease Treatment Options

  • Dr. Luis Paz-Ares

    Chair of the Medical Oncology Department, Hospital Universitario 12 de Octubre
    Associate Professor at the Universidad Complutense de Madrid
    Head of the Lung Cancer Unit at the CNIO (Spanish National Cancer Research Center), Madrid
    President of ASEICA (Spanish Association of Cancer Research)
  • Dr. Philippe Taniere

    Consultant Histopathologist
    Clinical Service Lead - Molecular Pathology Diagnostic Service
    University Hospitals Birmingham


Dr Philippe Taniere – Understanding biomarker testing for immunotherapy; PD-L1 (Programmed Death-Ligand 1) expression, Mismatch Repair (MMR) testing and the importance of Microsatellite Instability (MSI) and Tumor Mutational Burden

Dr Luis Paz-Ares - Overview of available immunotherapy options, the requirement for biomarker testing and how testing impacts immunotherapy prescription compared to other targeted therapies

You May Also Like
Loading Comments...
  • See More